Handelsbanken Fonder AB boosted its holdings in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) by 0.6% during the 1st quarter, HoldingsChannel reports. The fund owned 395,800 shares of the company’s stock after purchasing an additional 2,500 shares during the period. Handelsbanken Fonder AB’s holdings in Aerie Pharmaceuticals were worth $18,800,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of AERI. US Bancorp DE grew its holdings in Aerie Pharmaceuticals by 249.7% during the first quarter. US Bancorp DE now owns 570 shares of the company’s stock valued at $27,000 after purchasing an additional 407 shares during the last quarter. Truvestments Capital LLC acquired a new position in Aerie Pharmaceuticals during the first quarter valued at approximately $33,000. Bank of Montreal Can grew its holdings in Aerie Pharmaceuticals by 40.2% during the fourth quarter. Bank of Montreal Can now owns 1,060 shares of the company’s stock valued at $38,000 after purchasing an additional 304 shares during the last quarter. Quantamental Technologies LLC acquired a new position in Aerie Pharmaceuticals during the first quarter valued at approximately $41,000. Finally, Oppenheimer Asset Management Inc. acquired a new position in Aerie Pharmaceuticals during the first quarter valued at approximately $47,000.

AERI traded down $0.16 during trading on Wednesday, reaching $38.87. 898 shares of the company’s stock were exchanged, compared to its average volume of 532,236. Aerie Pharmaceuticals Inc has a fifty-two week low of $32.18 and a fifty-two week high of $74.75. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.47 and a quick ratio of 3.27. The company has a market capitalization of $1.76 billion, a P/E ratio of -8.22 and a beta of 0.82.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, May 7th. The company reported ($0.78) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.91) by $0.13. Aerie Pharmaceuticals had a negative net margin of 684.56% and a negative return on equity of 93.96%. The firm had revenue of $10.85 million for the quarter, compared to the consensus estimate of $12.66 million. On average, equities research analysts expect that Aerie Pharmaceuticals Inc will post -2.6 EPS for the current fiscal year.

Several brokerages have commented on AERI. Zacks Investment Research upgraded Aerie Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a report on Friday, March 22nd. ValuEngine upgraded shares of Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, May 9th. BidaskClub downgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, March 27th. Finally, Canaccord Genuity lowered their price objective on shares of Aerie Pharmaceuticals from $65.00 to $56.00 and set a “buy” rating on the stock in a research note on Friday, May 10th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and eleven have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $75.00.

WARNING: “Handelsbanken Fonder AB Acquires 2,500 Shares of Aerie Pharmaceuticals Inc (AERI)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2019/05/29/handelsbanken-fonder-ab-acquires-2500-shares-of-aerie-pharmaceuticals-inc-aeri.html.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Recommended Story: Bid-Ask Spread

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals Inc (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.